Acne Drugs Market Size to Reach USD 15.2 Billion by 2032 growing at 3.9% CAGR - Exclusive Report by Acumen Research and Consulting

Author: Acumen Research and Consulting

The global Acne Drugs Market size occupied USD 10.4 Billion in 2022 and is estimated to arrive at a size of around USD 15.2 Billion by 2032 rising with a CAGR of 3.9% during the forecasted years, as reported by Acumen Research & Consulting

The acne drug industry is expanding as a result of the high prevalence of acne, increased awareness of effective treatments, and an increase in prescription medication demand. Acne is a common skin condition that impacts individuals of every age and can have serious consequences for one's quality of life. The acne drugs industry focuses on developing and marketing acne treatments such as topical and oral medications.

Several key players dominate the industry, including Galderma, Johnson & Johnson, and Nestle Skin Health, which offers a variety of OTC and prescription acne medications. These companies invest a great deal of money in research and development to create new and innovative acne treatments, as well as marketing and advertising to increase product awareness.

New players in the acne medication market are also emerging, with a focus on developing natural and organic acne treatments. These businesses cater to customers who prefer organic and natural goods and are looking for alternatives to traditional medications. Furthermore, the industry is heavily controlled, with the FDA and other regulatory bodies overseeing acne medication safety and efficacy. The industry is also subject to pricing pressures, as many acne meds are available as generic products, which can minimize the profitability of branded products.

Acne Drugs Market Share

Acne Drugs Market Statistics

  • Global acne drugs market revenue accounted for USD 10.4 billion in 2022, with a 3.9% CAGR from 2023 to 2032
  • North American acne drugs market share occupied around 39% in 2022
  • Asia-Pacific acne drugs market growth is projected to attain a 4% CAGR from 2023 to 2032
  • By therapeutic class, retinoids grabbed over 32% share in 2022
  • Among formulation, the topical sub-segment gathered US$ 6.8 billion in revenue in 2022
  • Launch of novel acne treatment drugs is a recent acne drugs market trend

Request for a sample of this premium research report@ https://www.acumenresearchandconsulting.com/request-sample/3147

Acne Drugs Market Dynamics

Increasing Incidences of Acne Worldwide Expands the Acne Drugs Market Value

Acne's increasing global prevalence is a significant driver of growth in the acne drug market. Acne is a prevalent skin condition that affects people of all ages, and its prevalence is on the rise due to a variety of factors such as changing lifestyles, diets, and environmental factors. Acne affects approximately 85% of people at some point in their lives, causing it one of the most common skin conditions worldwide, according to the World Health Organization.

As the prevalence of acne rises, so does the demand for effective treatments to help manage and control the condition. As a result, the market for acne medications, including topical and oral treatments, is expanding. Acne's increasing prevalence has also resulted in a greater emphasis on research and development to create novel and creative treatments for the condition.

Growing Demand for Over-The-Counter (OTC) Acne Drugs to Generate Remarkable Acne Drugs Market Opportunities

The market for acne medications is expanding as a result of the rising demand for over-the-counter (OTC) acne medications. OTC acne medications are those that can be bought without a prescription and are used to treat mild to moderate acne. They are frequently used as the first-line treatment for acne and are widely available in drugstores, supermarkets, and online.

The rising popularity of over-the-counter acne medications is due to a number of factors, including their ease of use and accessibility, lower cost when compared to prescription medications, and the growing acceptance of self-care as well as self-treatment for minor medical conditions.

Companies in the industry are creating new and innovative products for this market segment, including organic and natural goods, in response to the growing demand for OTC acne drugs. This has resulted in a growing market for over-the-counter acne medications, such as salicylic acid, benzoyl peroxide, and sulfur.

Acne Drugs Market Segmentation

The global market has been categorized into type, therapeutic class, formulation, distribution channel, and region.

The type category is further divided into inflammatory acne and non-inflammatory acne. Therapeutic medications include retinoids, antibiotics, salicylic acid, benzoyl peroxide, and others. The acne drugs market by formulations is split into topical and oral. Distribution channels evaluated in the market include retail stores, pharmacies and drug stores, and e-commerce. North America, Latin America, Europe, Asia-Pacific, the Middle East, and Africa comprise the market's five regions (MEA).

Acne Drugs Market Share

Among all the types, inflammatory acne occupied the utmost market share in 2022 and is likely to do so in the coming years. Non-inflammatory acne growth rate, however, is expected to rise significantly throughout the forecast period.

According to our acne drugs industry analysis, the retinoid is the leading therapeutic class sub-segment with a majority of the share in the year 2022. Antibiotics as well as other therapeutic class segments will grow gradually in the market in the coming period.

As per the acne drugs market forecast, topical formulations have been dominating the segment for the past few years and will dominate in the future as well. However, oral formulations are anticipated to rapidly gain pace in the acne medication industry from 2023 to 2032.

According to our estimates, retail stores have performed well and captured a considerable market share in the acne drugs industry. This can be attributed to their widespread availability, strong presence of brands, and consistent branding efforts. Meanwhile, e-commerce websites have also performed strongly, with a rapidly increasing CAGR in recent years. We predict that the e-commerce distribution channel will continue to achieve significant market share and growth in the acne drugs market up until 2032.

Acne Drugs Market Regional Outlook

North America is the leading region in the industry, driven by the high prevalence of acne in the region and the increasing adoption of advanced treatment options. Several major market players, such as pharmaceutical companies and retail chains, are also based in the region.

Additionally, Europe is another important market for acne drugs, with a large patient pool and a growing demand for innovative acne treatments. Big investments in research and development activities have occurred in the region, resulting in the introduction of several new and advanced acne drugs.

The Asia-Pacific market for acne drugs is rapidly expanding, owing to the rising prevalence of acne and the increasing adoption of Western lifestyle habits. Substantial improvements in healthcare infrastructure and an increase in disposable income levels in the region have resulted in increased spending on healthcare products.

Acne Drugs Market Players

Some prominent acne drugs companies covered in the industry include Allergan Plc, Galderma S.A., GlaxoSmithKline Plc (Stiefel Laboratories, Inc.), Johnson & Johnson, Mylan N.V., Mayne Pharma Group Limited, Nestle Skin Health, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Sun Pharmaceutical Industries Limited, and Valeant Pharmaceuticals International, Inc.

In December 2021, Pfizer announced positive Phase 3 clinical trial results for abrocitinib, an investigational oral JAK3 inhibitor, for the treatment of moderate-to-severe atopic dermatitis (eczema). The trial found that abrocitinib was effective at reducing eczema symptoms while maintaining a safety profile consistent with previous research. The company intends to submit a New Drug Application (NDA) for abrocitinib to the US Food and Drug Administration (FDA) in the first half of 2022.

Click here to buy the Premium Market Research report https://www.acumenresearchandconsulting.com/buy-now/0/3147

Receive our personalized services and customization by clicking here https://www.acumenresearchandconsulting.com/request-customization/3147

Mr. Frank Wilson

Acumen Research and Consulting

USA: +13474743864

India: +918983225533

E-mail: sales@acumenresearchandconsulting.com